Publications

 
RECENT ARTICLES
 
Scientific Reports. November 07, 2017
Brault AC, Domi A, McDonald EM, Talmi-Frank D, McCurley N, Basu R, Robinson HL, Hellerstein M, Duggal NK, Bowen RA, Guirakhoo F
 
PLOS ONE, October 11, 2017
McCurley NP, Domi A, Basu R, Saunders KO, LaBranche CC, Montefiori DC, Haynes BF, Robinson HL
 
PLOS ONE, July 20, 2017
Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM,
Goepfert PA, Baden LR, Robinson HL, Yu X,  Gilbert PB, McElrath MJ, Huang Y, Tomaras GD, HIV Vaccine Trials Network (HVTN) 094 Study Group.
 
Curr Opin Virol. 2016 Apr;17:viii-x. doi: 10.1016/j.coviro.2016.05.006.
Robinson HL, Mulligan MJ.
 
Open Forum Infect Dis.2016 Feb 11;3(1):ofw034. doi: 10.1093/ofid/ofw034. eCollection 2016.
Chamcha V, Kannanganat S, Gangadhara S, Nabi R, Kozlowski PA, Montefiori DC, LaBranche CC, Wrammert J, Keele BF, Balachandran H, Sahu S, Lifton M, Santra S, Basu R, Moss B, Robinson HL, Amara RR

CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improved Protection against a Heterologous SIVE660 Mucosal Challenge.
Journal of Virology. 2014 September 1;88(17):9579-89.
Kwa S, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR.

The Immune Space: A Concept and Template for Rationalizing Vaccine Development.
AIDS Research and Human Retroviruses. 2014 June 26
Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI.

Local control of repeated-dose rectal challenges in DNA/MVA-vaccinated macaques protected against a first series of simian immunodeficiency virus challenges.
Journal of Virology. 2014 May;88(10):5864-9.
Kannanganant S, Gangadhara S, Lai L, Lawson B, Kozlowski PA, Robinson HL, Amara RR.

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles.
Journal of Infectious Diseases. 2014 July 1;210(1):99-110.
Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL, HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trial Network.

Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.
Clinical and Vaccine Immunology. 2013 February; 20(2): 205-10.
Polack F., Lydy S.H., Rota P., Bellini W., Adams R., Robinson, H., Griffin D.

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge.PHAS 2013. 2013 February 19; 110(8): 2975-80.
Patel V., Jalah R., Kulkarni V., Valentin A., Rosati M., Alicea C., von Gegerfelt A., Huang W., Guan Y., Keele B., Bess J., Piatak M., Lifson J., Williams W., Shen X., Tomaras G., Amara R., Robinson H., Johnson W., et. Al.

Non-neutralizing antibodies in prevention of HIV infection.
Expert Opinion on Biological Therapy. 2013 Feb; 13(2): 197-207.
Robinson H.

Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-DO3 DNA vaccine.
Human Vaccines & Immunotherapeutics. 2012 Nov 1; 8(11): 1654-8.
Polack F., Lydy S.H., Rota P., Bellini W., Adams R., Robinson, H., Griffin D.

SIVmac239 MVA vacccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.
Vaccine. 2012 Feb 21; 30(9): 1737-45.
Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, Johnson WE, Ferrari G, Hirsch VM, Felber BK, Pavlakis GN, Earl PL, Moss B, Amara RR, Robinson HL. 

Mining the mechanisms of an HIV vaccine.
Nature Medicine. 2012; 18(7): 1020:1021.
Robinson H.

Protective immunity from a germinal center sanctuary.
Nature Medicine. 2012; 18(11): 1614:1616.
Robinson H.

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/Modified Vaccinia Ankara simian immunodeficiency virus vaccine.
Journal of Infectious Diseases 2011 Jul 1;204(1):164-73.
Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, Hirsch V, Villinger F, Chennareddi L, Earl PL, Moss B, Amara RR, Robinson HL. 

Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.
Vaccine. 2011 Jul 26; 29(33): 5399-406.
Pillai VK, Kannanganat S., Penaloza-Macmaster P, Chennareddi L, Robinson HL, Blackwell J, Amara RR. 

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
Journal of Infectious Diseases 2011 Mar 1;203(5):610-9. Epub 2011 Jan 31.
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. 

HIGHLY CITED ARTICLES

Control of a mucosal challenge and prevention of AIDS in rhesus macaques by multiprotein DNA/MVA vaccine.
Science. 2001 Apr 6;292(5514):69-74.
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma H-L, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, and Robinson HL.

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.
Nature Medicine 1999 May;5(5):526-34.Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu S-L, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, and McClure HM.

DNA vaccines, protective immunizations by parenteral, mucosal, and gene gun inoculations.
Proceedings of the National Academy of Sciences of the United States of America. 1993 Dec 15;90(24):11478-82.
Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, and Robinson HL. CRITICAL STUDIES ON OUR PATH TO AN AIDS VACCINE

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.
Journal of Virology, 2009 May;83(9):4102-11. Epub 2009 Feb 18.
Zhao J, Lilin L, Montefiori, DC, Villinger F, Chennareddi L, Wyatt LS, Moss B and Robinson HL.

Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T cell response capable of coproducing gamma interferon and interleukin-2.
Journal of Virology 2005 Mar;79(6):3243-53.
Sadagopal S, Amara RR, Montefiori DC, Wyatt LS, Staprans SI, Kozyr NL, McClure HM, Moss B, Robinson HL.

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
AIDS Research and Human Retroviruses 2004 Jun;20(6):654-65.
Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL.

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
AIDS Research and Human Retroviruses 2004 Dec;20(12):1335-47.Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, Butera ST, Ellenberger DL, Yi H, Chennareddi L, Herndon JG, Wyatt LS, Montefiori D, Moss B, McClure HM, Robnson HL.

gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: Higher pre challenge antibody but poorer control of a live viral challenge.
AIDS Research and Human Retroviruses 2003 Oct;19(10):891-900.
Buge SL, Ma H-L, Amara RR, Wyatt LS, Earl PL, Villinger F, Montefiori DC, Staprans SI, Xu Y, O'Neil SP, Herndon JG, Hill E, Moss B, Robinson HL, and McNicholl JM.

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
Journal of Virology 2002 Jun;76(12):6138-46.
Amara RR, Smith JM, Staprans SI, Montefiori DC, Montefiori DC, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, Moss B, and Robinson HL.

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.
Nature Medicine 1999 May;5(5):526-34.
Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu S-L, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, and McClure HM.

Simian immunodeficiency virus DNA vaccine trial in macaques.
Journal of Virology 1996 Jun;70(6):3978-91.
Lu S-H, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, and Robinson HL.

SELECTED REVIEWS

T cell vaccines for microbial infections.
Nature Medicine 2005 Apr;11(4 Suppl):S25-32.
Robinson HL and Amara RR.

New hope for an AIDS vaccine.
Nature Reviews Immunology 2002 Apr;2(4):239-50.
Robinson HL.

The scientific future of DNA for immunization.
A position paper for the American Academy of Microbiology. 1997.
Robinson HL, Ginsberg H, Liu M, Davis H, and Johnston S.